LIQUID: Liquid Biopsies Integration for MGUS and MM diagnosis

In LIQUID, we propose to provide clear evidence for the use of combined liquid biopsies as diagnostic tools to differentiate MGUS from MM patients. This will allow a more accurate assessment of each patient while limiting the suffering associated with diagnosis. The parameters to be studied will be cfDNA, CTPC, EV-proteins, EV-miRNA and immune profile.
The main aims of LIQUID are the following:
1.Characterize the liquid biopsies from peripheral blood including cfDNA, CTPC, EV and immune profile in MM and MGUS patients;
2.Identify patient profiles of liquid biomarkers permitting the distinction between MGUS and MM patients;
3.Validate the identified liquid biomarkers profiles in a different cohort of patients;
4.Create a novel mathematical tool to be used in patient diagnosis that will combine different data of tumoral biology using minimally invasive tumour assessment.

One sub-project of LIQUID is GENOMME, Identification of non-invasive genetic biomarkers predicting response in Multiple Myeloma
In GENOMME we are comparing the genomic alterations found in matched bone marrow plasma cells, cfDNA and CTPCs to:
1.Study clonal evolution and its association with mechanisms of resistance
2.Define genetic biomarkers of diagnosis and prognosis
This project has been awarded by Janssen in 2022.